Sort by Industry
12/18/20
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/9/20
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium
10/8/20
Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma
6/24/20
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
10/29/19
Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting
10/7/19
Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma
7/29/19
Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/18/19
G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER
3/6/19
Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction
2/7/19
Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck
1/30/19
Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions
1/7/19
Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
12/6/18
Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors
10/18/18
Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma
7/30/18
Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis
5/31/18
Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema
4/16/18
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
3/28/18
Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma
3/15/18
G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer
3/5/18
Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
5/30/17
G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
3/29/17
G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
11/2/16
AgTech Accelerator Corporation Announces the Addition of Animal Health Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing
9/21/16